CRP and neoplasm: C-reactive protein (CRP) and Platelet lymphocyte ratio (PLR) could be considered as tumor markers for low-AFP HCC patients (Suner et al., 2019a), and possess parameter values for tumor growth and invasiveness (Suner et al., 2019b).